The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Effect of Chemical Modification and Nanoparticle Formulation on Stability and Biodistribution of siRNA in Mice
Open accessAbstract
Instability and inadequate biodistribution of double-stranded RNA are major drawbacks to the clinical use of RNA interference. This work compares chemical modification and nanoparticle formulation as strategies to improve the systemic delivery of small interfering RNA (siRNA). Variable levels of chemical modified siRNA, either naked or within nanoparticle, were intravenously injected into mice to study temporal stability and biodistribution detected by direct radioactive labeling or by northern blotting. Naked siRNA showed rapid renal clearance, with circulatory half-life of <5 minutes that could be extended to >30 minutes by cholesterol conjugation. The integrity of the chemically stabilized siRNA was maintained in blood for at least 30 minutes, whereas, unmodified siRNA duplex was degraded within 1 minute. Intact chemically modified siRNA could also be detected in all analyzed organs at 30 minutes but disappeared at 24 hours, except for heavy locked nucleic acid (LNA)-modified and cholesterol-conjugated siRNA in the lungs. Chitosan, liposomal, or JetPEI formulation greatly improved the stability and biodistribution of siRNA. Interestingly, high siRNA accumulation of the chitosan/siRNA formulation within the kidney was observed 24 hours postadministration. This comparative study highlights improvements to siRNA stability and pharmacokinetics, key determinants for development of clinically relevant RNAi therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency
Mao, H.-Q., Roy, K., Troung-Le, V. L., Janes, K. A., Lin, K. Y., Wang, Y., August, J. T., & Leong, K. W. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00361-8 · Cited by 1,228
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
siRNAs: applications in functional genomics and potential as therapeutics
Dorsett, Y., & Tuschl, T. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1345 · Cited by 909
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., & Aigner, A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302425 · Cited by 716
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
RNA Interference in Vitro and in Vivo Using a Novel Chitosan/siRNA Nanoparticle System
Howard, K. A., Rahbek, U. L., Liu, X., Damgaard, C. K., Glud, S. Z., Andersen, M. Ø., Hovgaard, M. B., Schmitz, A., Nyengaard, J. R., Besenbacher, F., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.010 · Cited by 585
Self-citationLocked nucleic acid (LNA) mediated improvements in siRNA stability and functionality
Elm n, J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki193 · Cited by 559
Formation and Intracellular Trafficking of Lipoplexes and Polyplexes
Elouahabi, A., & Ruysschaert, J.-M. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.006 · Cited by 462
Venturoli, D., & Rippe, B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00171.2004 · Cited by 461
Key issues in non-viral gene delivery
Pouton, C. W., & Seymour, L. W. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00048-9 · Cited by 440
The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing
Liu, X., Howard, K. A., Dong, M., Andersen, M. Ø., Rahbek, U. L., Johnsen, M. G., Hansen, O. C., Besenbacher, F., & Kjems, J. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.004 · Cited by 391
Self-citationHeidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Fisch, G., Dames, S., Löffler, K., Fechtner, M., Arnold, W., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302777 · Cited by 368
Thomas, M., Lu, J. J., Ge, Q., Zhang, C., Chen, J., & Klibanov, A. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502067102 · Cited by 366
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo
Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501753102 · Cited by 355
RNA interference and chemically modified small interfering RNAs
Manoharan, M. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.10.007 · Cited by 346
Poste, G. H., Bucana, C. D., Raz, A., Bugelski, P. J., Kirsh, R. L., & Fidler, I. J. (1982) · PubMed · Cited by 309
Howard, K. A., Paludan, S. R., Behlke, M. A., Besenbacher, F., Deleuran, B., & Kjems, J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.220 · Cited by 299
Self-citationPouton, C. W., & Seymour, L. W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00133-2 · Cited by 291
Oupicky, D., Ogris, M., Howard, K. A., Dash, P. R., Ulbrich, K., & Seymour, L. W. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0568 · Cited by 284
Self-citationHwang, H.-Y., Kim, I.-S., Kwon, I. C., & Kim, Y.-H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.02.003 · Cited by 254
Biodistribution of phosphodiester and phosphorothioate siRNA
Braasch, D. A., Paroo, Z., Constantinescu, A., Ren, G., Öz, O. K., Mason, R. P., & Corey, D. R. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.12.074 · Cited by 251
Grzelinski, M., Urban-Klein, B., Martens, T., Lamszus, K., Bakowsky, U., Höbel, S., Czubayko, F., & Aigner, A. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.751 · Cited by 234
van de Water, F. M., Boerman, O. C., Wouterse, A. C., Peters, J. G. P., Russel, F. G. M., & Masereeuw, R. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009555 · Cited by 217
Aigner, A. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2005.12.003 · Cited by 201
Improved silencing properties using small internally segmented interfering RNAs
Bramsen, J. B., Laursen, M. B., Damgaard, C. K., Lena, S. W., Ravindra Babu, B., Wengel, J., & Kjems, J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm548 · Cited by 192
Self-citationEvaluation of locked nucleic acid–modified small interfering RNA in vitro and in vivo
Mook, O. R., Baas, F., de Wissel, M. B., & Fluiter, K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0195 · Cited by 182
In Vivo Application of RNA Interference: From Functional Genomics to Therapeutics
Lu, P. Y., Xie, F., & Woodle, M. C. (2005) · Advances in Genetics · doi:10.1016/s0065-2660(05)54006-9 · Cited by 179
Pillé, J.-Y., Li, H., Blot, E., Bertrand, J.-R., Pritchard, L.-L., Opolon, P., Maksimenko, A., Lu, H., Vannier, J.-P., Soria, J., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1019 · Cited by 167
Dash, P. R., Read, M. L., Fisher, K. D., Howard, K. A., Wolfert, M., Oupicky, D., Subr, V., Strohalm, J., Ulbrich, K., & Seymour, L. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.3793 · Cited by 161
Self-citationPillé, J.-Y., Li, H., Blot, E., Bertrand, J., Pritchard, L. L., Opolon, P., Maksimenko, A., Lu, H., Vannier, J., Soria, J., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-248 · Cited by 140
Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts
Boulikas, T. (2004) · Oncology Reports · doi:10.3892/or.12.1.3 · Cited by 134
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
Geary, R. S., Yu, R. Z., & Levin, A. A. (2001) · PubMed · Cited by 133
Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo
Aigner, A. M. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-0984-y · Cited by 123
DEWOLF, H., Snel, C. J., Verbaan, F. J., Schiffelers, R. M., Hennink, W. E., & Storm, G. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.029 · Cited by 112
Polycation-based nanoparticle delivery for improved RNA interference therapeutics
Howard, K. A., & Kjems, J. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.12.1811 · Cited by 55
Self-citationViel, T., Boisgard, R., Kühnast, B., Jégo, B., Siquier-Pernet, K., Hinnen, F., Dollé, F., & Tavitian, B. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0133 · Cited by 49
Nanocarrier Stimuli‐Activated Gene Delivery
Howard, K. A., Dong, M., Oupický, D., Bisht, H. S., Bus, C., Besenbacher, F., & Kjems, J. (2006) · Small · doi:10.1002/smll.200600328 · Cited by 48
Self-citationStratford, S., Stec, S., Jadhav, V., Seitzer, J. L., Abrams, M. T., & Beverly, M. B. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.05.001 · Cited by 38
Tumor-Targeting Nanosystems for The Delivery of siRNA
Aigner, A. M. (2007) · Nanomedicine · doi:10.2217/17435889.2.4.569 · Cited by 4
Cited by
Chitosan-based formulations for delivery of DNA and siRNA
Mao, S., Sun, W., & Kissel, T. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.08.004 · Cited by 968
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
The growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Recent progress in development of siRNA delivery vehicles for cancer therapy
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.011 · Cited by 424
Therapeutic siRNA: State-of-the-Art and Future Perspectives
Friedrich, M., & Aigner, A. (2022) · BioDrugs · doi:10.1007/s40259-022-00549-3 · Cited by 396
Metadata
- Authors
- Gao, S., Dagnaes-Hansen, F., Nielsen, E. J. B., Wengel, J., Besenbacher, F., Howard, K. A., & Kjems, J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 17
- Issue
- 7
- Pages
- 1225-1233
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2159887227
- Cited by
- 286
- References
- 42
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.